DiagnoCure establishes U.S. commercial operations - Lease signed on service laboratory and key directors hired

    Ticker Symbol: CUR

    QUEBEC CITY, Dec. 5 /CNW Telbec/ - DiagnoCure Inc. (TSX: CUR), a life
sciences company commercializing high-value cancer diagnostic tests, today
announced that it signed a lease on a fully equipped service laboratory in
Philadelphia, PA. The company intends to use this lab to commercialize its
proprietary molecular tests for colorectal and other cancers. In addition, the
company has hired two seasoned directors to ensure optimal adoption of the
tests and their reimbursement by insurers.
    With the progress made on the optimization of the GCC test for colorectal
cancer and its forthcoming launch in 2008, DiagnoCure has decided to execute
its option to lease lab facilities from Targeted Diagnostics and Therapeutics,
Inc., the company from which it had acquired exclusive worldwide rights on the
GCC gene earlier this year.
    "Being able to offer our tests directly to physicians is key to our
business model," stated John Schafer, President and CEO of DiagnoCure.
"Molecular diagnostic tests are complex and by offering them through our own
service lab, we will be able to provide top quality results and support to the
ordering physicians. We are very excited about this first concrete step in
building our commercial operations in the U.S. where we intend to expand our
presence and establish our leadership."
    In support of commercialization efforts, Mr. Philip Wells, Sr. Director
of Reimbursement and Dr. Ronald Blum, Sr. Director Clinical Marketing recently
joined the company, reporting to Blair Shamel, Sr. Vice President of Corporate
Development. Mr. Wells previously worked at CV Therapeutics and Prometheus
Laboratories where he was responsible for reimbursement policy for both
laboratory tests and pharmaceutical products. At DiagnoCure, he will be
responsible for developing and implementing corporate strategies for gaining
reimbursement for the company's high-value tests. Dr. Blum comes from
Specialty Laboratories in Santa Monica, CA where he served as Vice President
of Marketing. Dr. Blum will be responsible for developing and implementing
strategies for educating the oncologists, surgeons and pathologists on the
clinical value of the company's proprietary tests for GCC and Shc proteins,
thus creating clinical demand.
    About those hires, John Schafer added: "We are pleased that high level
executives like Phil and Ron have chosen to join DiagnoCure as key team
members. We are building an organization of highly-experienced professionals
to bring key clinical tests to market."

    About DiagnoCure's proprietary tests

    The GCC gene has been shown in early studies to be of potential value in
patients with colorectal cancer to determine whether their disease has spread
outside the intestinal tract, which would help determine whether a patient
requires expensive and debilitating chemotherapy after surgery. A prospective,
five-year NIH-sponsored study of the test is nearing completion and is
expected to be available in 2008. The Shc protein assays have been shown to be
of potential value in colon, breast and other cancers to determine whether a
patient's cancer is at high risk of recurring and potentially, which treatment
type is likely to be effective.

    About DiagnoCure

    DiagnoCure (TSX: CUR) is a life sciences company commercializing
high-value cancer diagnostic tests and delivering lab services that increase
clinician and patient confidence in making critical treatment decisions.
DiagnoCure is currently preparing to launch the first GCC-based molecular test
for the management of colorectal cancer. In 2003, the Company entered into a
strategic alliance with Gen-Probe (NASDAQ:   GPRO) for the development and
commercialization of a second-generation test for PCA3, DiagnoCure's
proprietary molecular marker highly specific to prostate cancer. The test is
now available through laboratories in the U.S. using PCA3 analyte specific
reagents (ASR) from Gen-Probe, and in Europe as the CE-marked PROGENSA(TM)
PCA3 in vitro assay. In addition to its own research, the Company intends to
acquire or in-license additional promising cancer biomarkers from both
academic and commercial institutions. For more information visit

    Forward-looking statements

    This release contains forward-looking statements that involve known and
unknown risks, uncertainties and assumptions that may cause actual results to
differ materially from those expected. By their very nature, forward-looking
statements are based on expectations and hypotheses and also involve risks and
uncertainties, known and unknown, many of which are beyond DiagnoCure's
control. As a result, investors are cautioned not to place undue reliance on
these forward-looking statements. The forward-looking statements regarding the
outcome of research and development projects, clinical studies and future
revenues are based on management expectations. In addition, the reader is
referred to the applicable general risks and uncertainties described in
DiagnoCure's most recent Annual Information Form under the heading "Risk
Factors". DiagnoCure undertakes no obligation to publicly update or revise any
forward-looking statements contained herein.
    %SEDAR: 00003671EF

For further information:

For further information: Jean-Pierre Trudel, Jean-Pierre Trudel &
Associates, (514) 347-6111, jp.trudel@videotron.ca; DiagnoCure Inc., (418)
527-6100, communications@diagnocure.com

Organization Profile

DiagnoCure Inc.

More on this organization

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890